NCT02584933: Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 4
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be currently receiving treatment with ceritinib within a Novartis-sponsored study
Exclusions: 
https://ClinicalTrials.gov/show/NCT02584933

Comments are closed.

Up ↑